SuperworthAprea Therapeutics EPS APRE
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$1.08
- Latest quarter, Q2 FY26
- −$0.07
- Fiscal year 2025
- −$1.98
Aprea Therapeutics' earnings per share was −$1.08 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.07.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.98 | n/a |
| FY2024 | −$2.38 | n/a |
| FY2023 | −$3.99 | n/a |
| FY2022 | −$97.21 | n/a |
| FY2021 | −$35.00 | n/a |
| FY2020 | −$50.80 | n/a |
| FY2018 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.07 | n/a | −$1.08 | |
| Q1 FY26 | −$0.22 | n/a | −$1.54 | |
| Q4 FY25 | −$0.32 | n/a | −$1.98 | |
| Q3 FY25 | −$0.47 | n/a | −$2.15 | |
| Q2 FY25 | −$0.53 | n/a | −$2.32 | |
| Q1 FY25 | −$0.66 | n/a | −$2.37 | |
| Q4 FY24 | −$0.49 | n/a | −$2.38 | |
| Q3 FY24 | −$0.64 | n/a | −$2.81 | |
| Q2 FY24 | −$0.58 | n/a | −$3.03 | |
| Q1 FY24 | −$0.67 | n/a | −$3.32 | |
| Q4 FY23 | −$0.92 | n/a | −$3.99 | |
| Q3 FY23 | −$0.86 | n/a | −$3.99 |
Against its peers
Companies in Healthcare nearest Aprea Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| APREAprea Therapeutics | −$1.08 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.26 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aprea Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.